Karin Dahlman-Wright is a professor of molecular endocrinology and was made pro-vice-chancellor of Karolinska Institutet on 1 January 2016. On 18 February that same year, the government appointed her Karolinska Institutet’s acting vice-chancellor, a position she relinquished on 1 August 2017 to resume my previous title. From 2009 until August 2015 she was head of the Department of Biosciences and Nutrition, and in 2015 she was vice-dean of infrastructure. Between September 2013 and June 2015 she was KI Scientific Director at SciLifeLab with special responsibility for the national platforms, and was a member of SciLifeLab’s operational management. In 2001 she founded BEA, a core facility that provides advanced services in genomics and bioinformatics. From 1994 to 2000 she held the positions of line manager and project manager at Pharmacia and Upjohn. She also active in the Strategic Research Area in Diabetes at KI.

Her research is focused on studies of estrogen signaling with specific focus on type 2 diabetes and breast cancer. We study phenotypes of mouse models with tissue selective knock-out of estrogen receptors and relate this to molecular changes such as changes in global gene expression. She use different breast cancer cell models and functional genomics technologies, such as ChIP SEQ, global gene expression analysis and proteomics, to identify signaling pathways that can include possible targets for treatment of breast cancer.